Global trends, potential mechanisms and early detection of organ damage in SLE

Nature Reviews Rheumatology

Volumn 9, Issue 5, 2013, Pages 301-310

  Mak, Anselm ^a   Isenberg, David A ^b   Lau, Chak Sing ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALPHA INTERNEXIN ANTIBODY; AMINO TERMINAL TELOPEPTIDE; AUTOANTIBODY; CERULOPLASMIN; CXCL16 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; ESTROGEN RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MANNOSE BINDING LECTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2 ANTIBODY; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; OSTEOCALCIN; RANTES; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AMENORRHEA; ANTIBODY PRODUCTION; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; COGNITIVE DEFECT; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DISEASE ACTIVITY; EARLY DIAGNOSIS; ENDOTHELIAL PROGENITOR CELL; FRACTURE; FRACTURE RISK ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASTIC DISEASE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ANIMALS; ATHEROSCLEROSIS; COGNITION DISORDERS; EARLY DIAGNOSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877587422     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.208     Document Type: Review

References (99)

1. Mak, A., Cheung, M. W., Chiew, H. J., Liu, Y. & Ho, R. C. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin. Arthritis Rheum. 41, 830-839 (20126p
2. Lau, C. S. & Mak, A. The socioeconomic burden of SLE. Nat. Rev. Rheumatol. 5, 400-404 (20096p
3. Rahman, P., Gladman, D D., Urowitz, M. B., Hallett, D. & Tam, L, S. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93-96 (20016p
4. Chambers, S. A., Allen, E., Rahman, A. & Isenberg, D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48, 673-675 (20096p
5. Mok, C. C., Ho, C. T., Wong, R. W. & Lau, C. S. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J. Rheumatol. 30, 1513-1519 (20036p
6. Danila, M. I.et al. Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48, 542-545 (20096p
7. Guarize, J.,Appenzeller, S. & Costallat, L. T. Skin damage occurs early in systemic lupus erythematosus and independently of disease duration in Brazilian patients. Rheumatol. Int. 27, 483-487 (20076p
8. Wang, Y.et al. Autoantibodies closely relate to the elevation level of in vivo hydrogen peroxide and tissue damage in systemic lupus erythematosus. DNA Cell Biol. 25, 563-570 (20066p
9. Yung, S. & Chan, T. M. Anti-DNA antibodies in the pathogenesis of lupus nephritis - the emerging mechanisms. Autoimmun. Rev. 7, 317-321 (20086p
10. Yung, S., Cheung, K. F., Zhang, Q. & Chan, T. M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J. Am. Soc. Nephrol. 21, 1912-1927 (20106p
11. Yung, S.et al. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum. 60, 2071-2082 (20096p
12. Sun, K. H., Tang, S. J., Wang, Y. S., Lin, W. J. & You, R. I. Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2. Rheumatology (Oxford) 42, 154-161 (20036p
13. Wilson, A. M.et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc. Med. 15, 267-274 (20106p
14. Bultink, I. E., Teerlink, T., Heijst, J. A., Dijkmans, B. A. & Voskuyl, A. E. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64, 1362-1365 (20056p
15. Kiani, A. N.,Mahoney, J. A. & Petri, M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J. Rheumatol. 34, 1502-1505 (20076p
16. Xiao, Z. S.et al. Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int. 60, 1699-1704 (20016p
17. Lu, R., Hu, C. P., Wu, X. P., Liao, E. Y. & Li, Y. J. Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats. Comp. Med. 52, 224-228 (20026p
18. Oates, J. C., Shaftman, S. R., Self, S. E. & Gilkeson, G. S. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 58, 263-272 (20086p
19. Saxena, V.et al. Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J. Immunol. 180, 1903-1912 (20086p
20. Taniguchi, Y.et al. Role of transforming growth factor-beta 1 in glomerulonephritis. J. Int. Med. Res. 25, 71-80 (19976p
21. Becker-Merok, A., Eilertsen, G. O. & Nossent, J. C. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 37, 2039-2045 (20106p
22. Barreto, M.et al. Low frequency of CD4+CD25+ Treg in SLE patients: A heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol. 10, 5 (20096p
23. Font, J.et al. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46, 76-80 (20076p
24. Øhlenschlaeger, T., Garred, P., Madsen, H. O. & Jacobsen, S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N. Engl. J. Med. 351, 260-267 (20046p
25. Calvo-Alén, J.et al. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54, 1940-1945 (20066p
26. Stellato, C.et al. Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J. Immunol. 155, 410-418 (19956p
27. Ye, D. Q.et al. Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch. Dermatol. Res. 297, 108-113 (20056p
28. Sung, Y. K.et al. Interleukin10 gene polymorphisms are associated with the SLICC/ACR Damage Index in systemic lupus erythematosus. Rheumatology (Oxford) 45, 400-404 (20066p
29. Johansson, M., Arlestig, L., Moller, B., Smedby, T. & Rantapaa-Dahlqvist, S. Oestrogen receptor α gene polymorphisms in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 1611-1617 (20056p
30. Lundström, E.et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis- 2012-201760.6p
31. Diamond, B. Antibodies and the brain: Lessons from lupus. J. Immunol. 185, 2637-2640 (20106p
32. Aranow, C., Diamond, B. & Mackay, M. Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 36, 187-201, x-xi (20106p
33. Lapteva, L.et al. AntiNmethylDaspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505-2514 (20066p
34. Kowal, C.et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103, 19854-19859 (20066p
35. Gono, T.et al. NR2-reactive antibody decreases cell viability through augmentation of Ca(2+) influx in systemic lupus erythematosus. Arthritis Rheum. 63, 3952-3959 (20116p
36. Hanly, J. G.et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study. Arthritis Rheum. 58, 843-853 (20086p
37. Yoshio, T., Onda, K., Nara, H. & Minota, S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 54, 675-678 (20066p
38. Arinuma, Y., Yanagida, T. & Hirohata, S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 58, 1130-1135 (20086p
39. Lu X.Y.et al. Antialphainternexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS ONE 5, e11124 (20106p
40. Denburg, J. A.,Carbotte, R. M. & Denburg, S. D. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 37, 464-467 (19876p
41. Hanly, J. G.et al. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br. J. Rheumatol. 32, 291-296 (19936p
42. Spezialetti, R., Bluestein, H. G., Peter, J. B. & Alexander, E. L. Neuropsychiatric disease in Sjogren's syndrome: Anti-ribosomal P and anti-neuronal antibodies. Am. J. Med. 95, 153-160 (19936p
43. Kozora, E.,Ellison, M. C. & West, S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum. 51, 810-818 (20046p
44. DiFrancesco, M. W.et al. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: A pilot study. Arthritis Rheum. 56, 4151-4163 (20076p
45. Fitzgibbon, B. M.et al. Functional MRI in NPSLE patients reveals increased parietal and frontal brain activation during a working memory task compared with controls. Rheumatology (Oxford) 47, 50-53 (20086p
46. Mak, A., Ren, T., Fu, E. H., Cheak, A. A. & Ho, R. C. A prospective functional MRI study for executive function in patients with systemic lupus erythematosus without neuropsychiatric symptoms. Semin. Arthritis Rheum. 41, 849-858 (20126p
47. Ren, T,, Ho, R. C. & Mak, A. Dysfunctional cortico-basal ganglia-thalamic circuit and altered hippocampal-amygdala activity on cognitive set-shifting in non-neuropsychiatric, SLE. Arthritis Rheum. 64, 4048-4059 (20126p
48. Folsom, A. R.et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch. Intern. Med. 168, 1333-1339 (20086p
49. Simon, A., Chironi, G. & Levenson, J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 48, 392-396 (20066p
50. Thompson, T.et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum. 58, 835-842 (20086p
51. Asanuma, Y.et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (20036p
52. Rho, Y. H.et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J. Rheumatol. 35, 1789-1794 (20086p
53. Yiu, K. H.et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J. Rheumatol. 36, 2212-2217 (20096p
54. Halcox, J. P.et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653-658 (20026p
55. Furchgott, R. F. & Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (19806p
56. Corretti, M. C.et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force J. Am. Coll. Cardiol. 39, 257-265 (20026p
57. Mak, A., Liu, Y. & Ho, R. C. Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: A metaanalysis and metaregression. J. Rheumatol. 38, 1296-1303 (20116p
58. Lima, D. S.,Sato, E. I., Lima, V. C., Miranda, F. Jr & Hatta, F. H. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 29, 292-297 (20026p
59. El-Magadmi M.et al. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 110, 399-404 (20046p
60. Mak, A.et al. Lumbar spine bone mineral density predicts endothelial reactivity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 29, 261-268 (20116p
61. Asahara, T., Kawamoto, A. & Masuda, H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 29, 1650-1655 (20116p
62. Lau, K. K.et al. Incremental predictive value of vascular assessments combined with the Framingham Risk Score for prediction of coronary events in subjects of low-intermediate risk. Postgrad. Med. J. 84, 153-157 (20086p
63. Lau, K. K.et al. Burden of carotid atherosclerosis in patients with stroke: Relationships with circulating endothelial progenitor cells and hypertension. J. Hum. Hypertens. 21, 445-451 (20076p
64. Loomans, C. J.,De Koning, E. J., Staal, F. J., Rabelink, T. J. & Zonneveld, A. J. Endothelial progenitor cell dysfunction in type 1 diabetes: Another consequence of oxidative stress? Antioxid. Redox Signal. 7, 1468-1475 (20056p
65. Moonen, J. R.et al. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 9, R84 (20076p
66. Grisar, J.et al. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 47, 1476-1483 (20086p
67. Deng, X. L., Li, X. X., Liu, X. Y., Sun, L. & Liu, R. Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol. Int. 30, 1429-1436 (20106p
68. Hibbert B. et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries PLoS ONE 6 16413 (20116p).
69. Grisar, J.et al. Endothelial progenitor cells in active rheumatoid arthritis: Effects of tumour necrosis factor and glucocorticoid therapy. Ann. Rheum. Dis. 66, 1284-1288 (20076p
70. Distler, J. H.et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann. Rheum. Dis. 68, 163-168 (20096p
71. Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL): A new marker of kidney disease. Scand. J. Clin. Lab. Invest. Suppl. 241, 89-94 (20086p
72. Pitashny, M.et al. Urinary lipocalin2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56, 1894-1903 (20076p
73. Nielsen, B. S.et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38, 414-420 (19966p
74. Wu, T et al. Elevated urinary VCAM1, Pselectin, soluble TNF receptor1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179, 7166-7175 (20076p
75. Abd-Elkareem, M. I., Al Tamimy, H. M., Khamis, O. A., Abdellatif, S. S. & Hussein, M. R. Increased urinary levels of the leukocyte adhesion molecules ICAM1 and VCAM1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin. Exp. Nephrol. 14, 548-557 (20106p
76. Kiani, A. N.et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J. Rheumatol. 39, 1231-1237 (20126p
77. Ikeda, Y Fujimoto, T., Ameno, M., Shiiki, H. & Dohi, K. Relationship between lupus nephritis activity and the serum level of soluble VCAM1. Lupus 7, 347-354 (1998
78. Spronk, P. E., Bootsma, H., Huitema, M. G., Limburg, P. C. & Kallenberg, C. G. Levels of soluble VCAM1, soluble ICAM1, and soluble Eselectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 97, 439-444 (19946p
79. Avihingsanon, Y.et al. Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int. 69, 747-753 (20066p
80. Reyes-Thomas, J., Blanco, I. & Putterman, C. Urinary biomarkers in lupus nephritis. Clin. Rev. Allergy Immunol. 40, 138-150 (20116p
81. Schwartz, N.et al. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27, 242-250 (20066p
82. Varghese, S. A.et al. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18, 913-922 (20076p
83. Suzuki, M.et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr. Res. 65, 530-536 (20096p
84. Zhang, X.et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74, 799-807 (20086p
85. Cauley, J. A.et al. Clinical risk factors for fractures in multi-ethnic women: The Women's Health Initiative. J. Bone Miner. Res. 22, 1816-1826 (20076p
86. van den Bergh, J. P., van Geel, T. A., Lems, W. F. & Geusens, P. P. Assessment of individual fracture risk: FRAX and beyond. Curr. Osteoporos. Rep. 8, 131-137 (20106p
87. Fraser, L. A.et al. Fracture prediction and calibration of a Canadian FRAX(R.) tool: A population-based report from CaMos. Osteoporos. Int. 22, 829-837 (20116p
88. Mak, A., Lim, J. Q., Liu, Y., Cheak, A. A. & Ho, R. C. Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol. Int. http://dx.doi.org/10.1007/s00296-012-2389-1.6p
89. Mok, C. C.et al. Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomised double-blinded placebo-controlled trial. Ann. Rheum. Dis. 70, 778-784 (20116p
90. Baker-LePain, J. C., Nakamura, M. C., Shepherd, J. & von Scheven, E. Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 50, 611-619 (20116p
91. Abu-Shakra, M., Urowitz, M. B., Gladman, D. D. & Gough, J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J. Rheumatol. 22, 1259-1264 (19956p
92. Manger, K.et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann. Rheum. Dis. 61, 1065-1070 (20026p
93. Mok, C. C. Mak, A., Chu, W. P., To, C. H. & Wong, S. N. Long-term survival of southern Chinese patients with systemic lupus erythematosus: A prospective study of all age-groups. Medicine (Baltimore) 84, 218-224 (20056p
94. Cervera, R.et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (20036p
95. Ruiz-Irastorza, G., Egurbide, M. V., Ugalde, J. & Aguirre, C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch. Intern. Med. 164, 77-82 (20046p
96. Bernatsky, S.et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (20066p
97. Nossent, J.et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus 16, 309-317 (20076p
98. Urowitz, M. B. Gladman, D. D., Tom, B. D., Ibanez, D. & Farewell, V. T. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J. Rheumatol. 35, 2152-2158 (20086p
99. Kang, K. Y.et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus 20, 989-997 (20116p